Dylan Dunn

Dylan Dunn

Auto-generated profile, based on publicly available information

Dylan Dunn

Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore, USA

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2024 in npj Vaccines
Verified
Journal Article
Open access
PDF file
GDGirmay Desalegn
Girmay Desalegn
CTChitradevi S. Tamilselvi
Chitradevi S. Tamilselvi
JLJose M. Lemme-Dumit
Jose M. Lemme-Dumit
SHShannon J. Heine
Shannon J. Heine
DDDylan Dunn
Dylan Dunn
MPMarcela F. Pasetti
Marcela F. Pasetti
Diarrhea caused by Shigella has been associated with high morbidity and mortality in young children worldwide. There are no licensed vaccines, and those clinically advanced have restricted coverage as they elicit serotype-specific immunity while disease is caused by multiple circulating serotypes. Our group had previously reported a close association between serum antibodies to the Shigella virulence factor VirG (or IcsA) and clinical protection in infected individuals. VirG is highly conserved among Shigella strains and appealing as a broad-spectrum vaccine candidate. In this study, we investigated the immunogenicity and protective capacity of VirG as a subunit vaccine in mice. The surface-exposed alpha (α) domain of VirG (VirGα) was produced as a recombinant protein. This region has almost identical immune reactivity to full-length VirG. Administered intramuscularly with alum, VirGα elicited robust immune responses and high protective efficacy against S. flexneri 2a and S. sonnei. Almost complete protection was afforded by VirGα given intranasally with the E. coli double mutant heat-labile toxin (dmLT). VirGα-specific antibodies recognized VirG expressed on live Shigella, and blocked Shigella adhesion and invasion to human colonic cells. These results show for the first time that VirGα is a promising cross-protective vaccine candidate to prevent Shigella infection.

13 January 2025 in npj Vaccines
Verified
Journal Article
Open access
PDF file
GDGirmay Desalegn
Girmay Desalegn
CACharlotte Abrahamson
Charlotte Abrahamson
KTK. Ross Turbyfill
K. Ross Turbyfill
LPLucy Pill-Pepe
Lucy Pill-Pepe
LBLeslie Bautista
Leslie Bautista
MPMarcela F. Pasetti
Marcela F. Pasetti
Dysentery caused by Shigella species remains a major health threat to children in low- and middle-income countries. There is no vaccine available. The most advanced candidates, i.e., O-polysaccharide (OPS)-based conjugates, have limited coverage—only against the immunizing serotype. Vaccines based on Shigella conserved proteins are sought for their simplicity and capacity to prevent disease caused by multiple serotypes. We previously reported the broad protective capacity of VirGα, a conserved surface-exposed domain of Shigella virulence factor. Seeking to refine the vaccine antigenic target and achieve scalable manufacturing compatible with Good Manufacturing Practices, we mapped linear B-cell epitopes spanning the entire VirG protein sequence by probing the immune reactivity of 10-mer peptides (overlapping 4–8 aa) with sera from Shigella-infected rhesus monkeys. The surface-exposed VirG53–353 subregion of the passenger α-domain demonstrated the highest and strongest immunoreactivity. VirG53–353 was produced efficiently at a large scale (>150 mg/L) using cell-free protein synthesis. When administered to mice intramuscularly, VirG53–353 elicited robust antibody responses and conferred high levels of protection against the three most prevalent Shigella serotypes (S. flexneri 2a, 3a, and S. sonnei). VirG53–353 evoked the production of Th2-type cytokines by spleen cells from vaccinated mice. A new universal Shigella vaccine based on VirG53–353 meets the World Health Organization’s preferred product specifications. The target antigen refinement and production improvement described here will facilitate the first-in-human studies.

9 October 2026 in npj Vaccines
Verified
Journal Article
Open access
PDF file
GDGirmay Desalegn
Girmay Desalegn
LBLeslie Bautista
Leslie Bautista
LPLucy Pill-Pepe
Lucy Pill-Pepe
CACharlotte Abrahamson
Charlotte Abrahamson
JLJose Lemme-Dumit
Jose Lemme-Dumit
MPMarcela F. Pasetti
Marcela F. Pasetti
Shigella species are a major cause of diarrheal diseases and child mortality worldwide. There is no licensed vaccine to prevent shigellosis, and most candidates target the bacterial O-polysaccharide, which limits their coverage to the vaccine serotype. Conserved Shigella proteins capable of eliciting broadly protective immunity are compelling alternatives for overcoming serotype-restricted responses. We previously reported that VirG is a broadly protective Shigella antigen. Here, we demonstrate the antimicrobial function and cross-protective efficacy of VirG-specific antibodies. Immunization with VirG-derived constructs induced high and durable antigen-specific IgG responses in rabbits, and passive transfer of VirG-specific rabbit antisera conferred significant protection (57.1-75.0%) in mice against lethal S. flexneri 2a and S. sonnei challenge. VirG-specific antibodies recognized native VirG expressed unipolarly by live bacteria and exhibited a range of antimicrobial activities, including bactericidal and opsonophagocytic killing, and inhibition of bacterial adherence and invasion of human colonoids. We demonstrate, for the first time, that Shigella protein-specific antibodies can mediate Shigella killing. In summary, VirG-directed antibodies exhibited robust antimicrobial activity and mediated cross-serotype protection. These findings support VirG as a promising component of next-generation protein-based Shigella vaccines.